All News

Germline platelet polygenic risk score predicted a 37% higher risk of death in patients with renal cell carcinoma, mediated by sustained thrombocytosis.

Three Neuroendocrine Tumor Research Foundation grant winners outlined research that aimed to deliver biology-driven strategies to patients.

Findings from the phase 3 SWOG 1826/CA209-8UT trial support the regulatory decision for this lymphoma population.

It’s unlikely guidelines recommend screening patients younger than 45 years for colorectal cancer, according to Yoanna S. Pumpalova, MD.

The resubmission occurred after discussions with the FDA in January 2026, where the agency requested additional data to support its review.

Patients with high-risk or intermediate-risk disease may benefit from allogeneic stem cell transplantation as a potentially “curative approach.”

Although survival outcomes were comparable among the 3 PD-1 inhibitors in the overall cohort, tislelizumab and sintilimab showed superior PFS in PD-L1–positive subgroups, suggesting biomarker-driven therapeutic selection.

The NHS-Galleri study showed that multi-cancer screening with the Galleri test did not reduce the number of cancers found at stage III or IV.

Rusfertide could become a part of every patient’s treatment history for polycythemia vera, according to Andrew Kuykendall, MD.

Erin Baurle, PsyD, discussed sleep-wake disturbances in patients with cancer and the efficacy of a CBT-I pilot program.

FG001 is an investigational uPAR-targeting fluorophore designed to provide real-time illumination of aggressive brain tumors during surgical resection.

The phase 3 TALAPRO-3 study met its primary end point, showing a clinically meaningful reduction in the risk of progression or death in HRR-mutant HSPC.

The addition of Bacillus Calmette-Guérin to ERBT significantly reduced 1-year recurrence rates among patients with high-risk, muscle-invasive disease.

Ben Brewer, PsyD, discussed the 5 core components of cognitive behavioral therapy for insomnia.

Donor availability may influence the treatment decision-making process regarding the use of transplantation for those with myelofibrosis.

This study aims to understand the degree of influence of the severity of lymphedema on quality of life in patients with breast cancer–related lymphedema during the maintenance phase.

Sacituzumab govitecan and pembrolizumab were recommended as category 1 regimens for metastatic triple-negative breast cancers based on 2 phase 3 trials.

Benjamin Garmezy, MD discussed the potential of a GSPT1 molecular glue degrader and a trispecific T-cell engager in treating select prostate cancers.

For patients with more aggressive disease, the addition of chemotherapy to the ARPI/ADT backbone may optimize efficacy outcomes without comprising safety.

Persistent training and workflow gaps were listed as potential barriers of AYA care among oncologists.

The irinotecan-based ChemoSeed delivery mechanism is currently under investigation for patients with malignant glioma in a registrational phase 2 trial.

The MyChoice CDx was approved based on its performance determining HRD status and stratifying patients in the phase 3 PRIMA trial.

In the non-HLA-A*02 arm of the FLAMINGO-1 trial, breast recurrence rates were less than 1% following treatment with GLSI-100.

The primary end point of PFS was met in the phase 3 FOURLIGHT-1 trial assessing atirmociclib plus fulvestrant in patients with HR+/HER2– breast cancer.

In each decade since the launch of the journal ONCOLOGY, cancer care has evolved, and with it the finances and costs associated with these improving treatments.

Julian Hong, MD, MS, stated that the demand for highly specialized teams trained to combat the onset of mental health disorders outpaces the supply.

FcRH5 is emerging as a potentially highly active target for cellular therapies in multiple myeloma care, said Natalia Neparidze, MD.

Julian Hong, MD, MS, discussed an analysis showing that patients with cancer and new mental health disorders have an increased risk of all-cause mortality.

According to a study published in Cancer, new-onset mental health disorders increased the risk of all-cause mortality in patients with cancer.

Adverse effects of novel immunotherapies appear controllable compared with chemotherapy in hematologic malignancies, according to Guenther Koehne, MD.